Embrex and Shenzhen Neptunus announce joint project
Embrex has delivered an Egg Remover system and an Inovoject system to Shenzhen Neptunus Interlong Bio-technique (SNI). These have been installed in SNI's human influenza vaccine manufacturing facility at High-Tech Industrial Park Guangming, Shenzhen.
The high-speed automated Egg Remover system identifies and removes infertile eggs and "early dead' embryos on days 9 to 11 of incubation.
The viable eggs then proceed for inoculation with the influenza virus using the Inovoject system, which injects eggs at a rate of approximately 30,000 eggs/hour.
The system is part of meeting the critical technical and regulatory needs of human flu vaccine producers in many countries, including a proprietary sanitation system which cleans needles after the injection of every egg, thus minimising cross-contamination between eggs.
The manufacturing facility, which has recently completed construction, is believed to be the largest and most advanced human influenza vaccine production facility in China.
Govt announces plan to boost medical science manufacturing
The Australian Government has released the Medical Science Co-investment Plan as part of its...
Early-bird rates and award opportunities at Accreditation Matters
It's just 11 weeks until NATA's accreditation conference, Accreditation Matters. Award...
Aust Academy of Science announces 2024 honorific awards
Researchers from around the country have been recognised by the Australian Academy of Science for...